PearlBone gets FDA clearance for world's largest orthopaedic market

Marine Biomedical, a biotech company in Western Australia, has received FDA clearance for its innovative bone graft substitute, PearlBone. This product is the first of its kind to utilize mother-of-pearl, also known as nacre, harvested from pearl shells. PearlBone is designed to repair bone fractures, marking a significant advancement in orthopedic treatment.

The iridescent substance, originally used for decorative purposes, has now proven effective for bone repair and regeneration. With the United States being the world's largest orthopedics market, valued at $1.1 billion, Marine Biomedical's product could greatly impact patient care. However, regulatory approval is just the beginning of the journey.

The company must still prove PearlBone's safety and efficacy against existing bone grafts. Additionally, they hope to bring the product to Australian patients and expand into other treatments like dental work. The biotech company formed in 2021 as a collaboration between Willie Creek Pearls, a local pearling business, and the University of Western Australia.

The harvested shells undergo cleaning and preparation before being used in the manufacturing process. While there is a plentiful supply of pearl shells for current needs, demand could potentially impact future availability. The availability of such an abundant resource in Western Australia could lead to broader industry involvement in supplying the product.

Professor Kevin Pfleger from the University of Western Australia expressed excitement about the achievement, emphasizing the importance of regulatory approval for future market entry in Australia.